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Abstract
Purpose To compare the bioavailability (BA) and phar-
macokinetic (PK) properties and to demonstrate the bio-
equivalence (BE) between two active product ingredient
(API) sources of eslicarbazepine acetate (ESL) in healthy
volunteers.
Design, subjects and methods Forty healthy male and
female subjects aged 18–40 years were randomized to
treatment with 400 or 800 mg ESL marketed (MF) for-
mulation [current active pharmaceutical ingredient (API)
source] and 400 or 800 mg ESL to-be-marketed (TBM)
formulation (new API source) under a gender-balanced,
two-period, two-sequence crossover open-label study
design. Subjects were assigned to receive either 400 or
800 mg ESL dose strengths, and each was randomly
administered on two occasions—either a single oral tablet
of MF or a single oral tablet of TBM—separated by a
washout period of at least 7 days. Formulations were to be
considered bioequivalent if, for both 400 or 800 mg ESL
dosage strengths, the test (TBM)/reference (MF) geometric
mean ratios (GMR) and 90 % confidence intervals (90 %
CI) of the area under the plasma concentration-time curve
(AUC) and peak plasma concentration (Cmax) were within
the predetermined range of 80–125 %.
Results Test/reference GMR (90 % CI) for the Cmax and
AUC was respectively 100 % (94–109 %) and 96 %
(94–98 %) following 400 mg ESL and 100 % (95–105 %)
and 100 % (97–103 %) following 800 mg ESL.
Conclusion Oral tablet formulations of either 400 or
800 mg ESL from the new API source were found to be
bioequivalent to the corresponding marketed Zebinix
formulation according to the regulatory definition of
bioequivalence.
1 Introduction
Eslicarbazepine acetate (ESL) is a once-daily anticonvul-
sant approved in 2009 by the European Medicines Agency
(EMA) as adjunct therapy in adults with partial-onset sei-
zures (POS), with or without secondary generalization.
ESL is structurally distinct from carbamazepine (CBZ) and
oxcarbazepine (OXC), although the three compounds are
dibenz[b,f]azepine derivatives [1]. This molecular distinc-
tion results in differences in metabolism [2]. CBZ and ESL
do not share any common metabolite and, contrarily to
CBZ, ESL is not susceptible to metabolic auto-induction
[3, 4].
Following oral administration, ESL undergoes extensive
first pass hydrolysis to its major active metabolite es-
licarbazepine [also known as (S)-licarbazepine] [5–9], which
represents approximately 95 % of circulating active moie-
ties and is believed to be responsible for its antiseizure effects
[10–14], most likely through blockade of voltage-gated
sodium channels and type T calcium channels [15, 16].
ESL is currently available in the form of tablets for oral
administration. A new active pharmaceutical ingredient
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(API) source was brought on board, and since the tablets
manufactured with it dissolve somewhat faster than those
manufactured with the current API (data on file), the
in vivo bioavailability (BA) of ESL and its metabolites was
deemed uncertain by EMA.
The most important property of any non-intravenous
dosage form (e.g., oral) is the ability to deliver the API to
the bloodstream in an amount sufficient to cause the
desired response. This property of a dosage form has his-
torically been identified as bioavailability. BA captures two
essential features, namely how fast the drug enters the
systemic circulation (rate of absorption) and how much of
the nominal strength enters the body (extent of absorption)
[17]. Moreover, in the management of epilepsy that
requires treatment for years, the BA of the anticonvulsant
drug should not fluctuate. It may lead to intoxication or
seizures may relapse [18].
The aim of this study was the assessment of the BA and
pharmacokinetic (PK) properties of the ESL formulation
with the new API source (Test) and to determine its bio-




This study (trial registration EudraCT No. 2010-022478-
15) was a two-center (Biotrial SA, Rennes and Paris,
France) phase 1 study to demonstrate the BE between two
API sources of ESL at two dose strengths (400 and
800 mg) in 40 (20 per dosage strength) healthy male and
female subjects under an open-label, randomized, gender-
balanced, two-period, two-sequence, crossover study
design.
The study design consisted of two treatment periods
separated by a washout period of at least 7 days between
doses. In one of the two treatment periods, subjects
received either a single oral dose of 400 or 800 mg ESL of
the marketed (MF) formulation—current API source
(Zebinix). In the other treatment period, a single oral dose
of 400 or 800 mg ESL of the to-be-marketed (TBM) for-
mulation—new API source—was administered. ESL tab-
lets from both formulations were manufactured by BIAL-
Portela & Co., SA, S. Mamede do Coronado, Portugal.
Subjects were required to attend the research facilities
for a follow-up visit 7–14 days after clinical discharge
(72 h post-dose) of the last treatment period or early dis-
continuation. Subjects were admitted to the research
facilities for both treatment periods on the day before
(Day-1) the dosing day (Day 1) and resided in the research
facilities until at least the 24 h post-dose (Day 2)
procedures. The Day 2 (36 h post-dose) to Day 4 (72 h
post-dose) assessments were performed in an ambulatory
way. Plasma levels of parent drug (ESL) are usually
undetectable. In the present study an achiral method was
used, thus not allowing to distinguish between es-
licarbazepine and its minor metabolite, (R)-licarbazepine;
in such cases, the mixture is reported as BIA 2-005
[19, 20].
ESL was administered as a single dose under a two-per-
iod, two-sequence crossover design because single-dose PK
studies to demonstrate BE are generally more sensitive in
assessing release of the drug substance from the drug product
into the systemic circulation. Due to the fact that two for-
mulations are to be compared a non-replicate crossover, a
two-period and two-sequence design was chosen. The ESL
dosage regimen was chosen from the Zebinix dose
strengths already marketed (400 and 800 mg).
The within-subject coefficient of variation of AUC0–?
and Cmax observed in previous studies with ESL was
\15 %. It was estimated for each dosage strength group
that with 16 subjects an overall power above 0.8 is attained
in an equivalence range of 80 to 125 % with a a value of
0.05 [21, 22]. Twenty subjects allowed for eventual drop-
outs and balancing for gender (i.e., 16 subjects completing
each group).
The studies were conducted according to the Helsinki
Declaration, ICH Good Clinical Practice recommendations
and applicable local regulations. The studies were approved
by an Independent Ethics Committee (CPP—Comite´ de
Protection des Personnes, Ouest VI, Brest, France) and the
French Medicines Agency (AFSSAPS). Written informed
consent was obtained for each study participant.
2.2 Population
Potential male and female subjects were screened for eli-
gibility within 28 and 2 days of admission to the first
treatment period. Screening consisted of discussion of
informed consent, medical history, physical examination,
vital signs, 12-lead ECG, clinical laboratory tests (hema-
tology, plasma biochemistry, coagulation, urinalysis, viral
serology, alcohol and drugs of abuse screen, and urine
pregnancy test) and review of the selection criteria. Sub-
jects were to be aged 18–55 years, within 18–25 kg/m2 of
body mass index (BMI) and non-smokers or smokers of
\10 cigarettes per day; women had to be pre-menopausal
and use double barrier or intrauterine device pregnancy
protection. No medication other than the study drugs or
necessary for the treatment of adverse events (AEs) was
allowed from the initial day of screening until final
discharge.
On dosing days, subjects had an overnight fast for at
least 10 h before dosing and remained fasted until 4 h post-
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dose. Water drinking was allowed as desired except for 1 h
before and after dosing. Products were administered, in the
morning with approximately 240 mL of water.
Subjects were requested to abstain from strenuous
physical activity, consumption of grapefruit juice, alcohol
and stimulating beverages containing xanthine derivatives
for 48 h prior to dosing and during each treatment period.
Subjects were also instructed to abstain from smoking for
2 h prior to until 24 h after drug administration at each
treatment period.
2.3 Blood Sampling and Plasma Drug Assays
Plasma concentrations of ESL and BIA 2-005 were deter-
mined using a validated liquid chromatography coupled to
tandem mass spectrometry (LC MS/MS) method in com-
pliance with Good Laboratory Practices (GLP).
Blood samples (4 mL of venous blood) were drawn by
direct venipuncture or via an intravenous catheter into
heparin-lithium vacutainers before the ESL dose and then
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-
dose.
After collection, blood samples were immediately cen-
trifuged at approximately 1,500g for 10 min at 4 C. Prior
to shipment to the laboratory for the analytical assays
(Swiss Bioanalytics AG, Birsfelden, Switzerland), the
resulting plasma was separated into aliquots of 0.75 mL
and stored at -20 C. The lowest level of quantification
(LLOQ) was at 10 ng/mL [19, 20].
2.4 Pharmacokinetic Assessments and Statistical
Analysis
Plasma levels of parent drug (ESL) are usually below the
limit of quantification at almost all sampling times.
Therefore, pharmacokinetic analysis was to be done for the
main metabolite (BIA 2-005).
The following pharmacokinetic parameters for BIA
2-005 were derived from the individual plasma concen-
tration-time profiles: maximum observed plasma concen-
tration (Cmax); time of occurrence of Cmax (tmax); area
under the plasma concentration versus time curve (AUC)
from time zero to the last sampling time at which con-
centrations were at or above the limit of quantification
(AUC0–t) and AUC from time zero to infinity (AUC0–?),
calculated by the linear trapezoidal rule; apparent terminal
rate constant, calculated by log-linear regression of the
terminal segment of the concentration versus time curve
(kz); apparent terminal half-life (t), calculated from ln 2/
kz. Descriptive statistics and individual pharmacokinetic
were determined.
For the evaluation of the formulation bioequivalence, the
parameters AUC0–?, AUC0–t and Cmax of BIA 2-005 were
the primary variables. The test procedure was analogous to
equivalence testing. For each ESL dosage strength, an
analysis of variance (ANOVA) was performed using log-
transformed data for Cmax, AUC0–t and AUC0–? of BIA
2-005 with sequence, period and treatment as fixed effects
and subject within sequence as random effect. The 90 %
confidence intervals (90 % CI) for the test/reference geo-
metric mean ratio (GMR) of BIA 2-005 Cmax, AUC0–t and
AUC0–? was calculated. In accordance with the guidelines
for bioequivalence testing, bioequivalence was assumed
when the ratio test/reference fell within the 90 % CI 80–125
reference range. The alpha error was set at 0.05 to define
statistical significance. The pharmacokinetic parameters
and analyses were calculated using WinNonlin Version 5.2
(Pharsight Corporation, Mountain View, CA, USA). The
statistical package SAS version 9.2 (SAS Institute Inc,
Cary, NC, USA) was used in some computations.
2.5 Safety Assessments
Safety and tolerability assessments included routine labo-
ratory tests (blood chemistries, hematological profile,
coagulation and urinalysis), physical examination, ECG
and vital signs. Any undesirable sign, symptom or medical
condition occurring after starting the study, whether
reported spontaneously or when prompted, was recorded
regardless of suspected relation to the study medications.
3 Results
3.1 Population
A total of 40 healthy subjects were randomized to the
study, 20 (20) in each dosage strength (400 and 800 mg
ESL).
The overall mean ± SD (range) demographic data were
as follows: age = 35.7 ± 10.6 (range 20–54) years;
height = 171 ± 9 (156–191) cm; BMI = 22.1 ± 1.9
(18.1–24.7) kg/m2. All subjects were exposed to ESL.
Twenty (20) subjects (11 males and 9 females) received
a single oral tablet of 400 mg ESL from both MF and TBM
formulations. Thus, all subjects completed both periods of
the 400 mg dosage strength and were available for PK
analysis.
Twenty (20) subjects (10 males and 10 females)
received a single oral tablet of 800 mg ESL of the MF
formulation but only 18 subjects received a single oral
tablet of 800 mg ESL of the TBM formulation. Two (2)
subjects discontinued the study before dosing on their
second treatment period (ESL 800 mg TBM): one subject
presented a positive result for opiates due to the intake of
antitussive syrup, and the other withdrew the informed
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consent for personal reasons. Thus, 18 (18) subjects (10
males and 8 females) completed both periods of the




ESL (parent) plasma concentrations were systematically
found to be below the limit of quantification; therefore, the
concentration-time profiles of ESL could not be displayed
nor the PK parameters calculated. Thus, PK analysis was
done exclusively for the main metabolite (BIA 2-005).
3.2.2 BIA 2-005
Mean plasma concentrations over time of BIA 2-005 fol-
lowing a single oral dose of ESL 400 mg MF and TBM
formulations and ESL 800 mg MF and TBM formulations
are presented in Fig. 1. Plasma drug concentration-time
curves show that the mean concentrations of BIA 2-005
were similar for the two formulations (MF and TBM) over
the entire sampling period and for both 400 and 800 mg
dose strengths (Fig. 1).
Following 400 mg ESL, the BIA 2-005 mean Cmax
values of the test (ESL 400 mg TBM) and reference (ESL
400 mg MF) formulations were 6.4 and 6.3 lg/mL,
respectively. The median Tmax values were 2.0 h for both.
Results for the extent of absorption, as determined from
mean AUC0–t and AUC0–? values, were 105.9 and
106.6 lg h/mL, respectively, after administration of the
Test formulation and 110.3 and 111.1 lg h/mL, respec-
tively, after administration of the reference formulation
(Table 1).
Following 800 mg ESL, the BIA 2-005 mean Cmax
values of the test (ESL 800 mg TBM) and reference (ESL
800 mg MF) formulations were 12.81 and 12.95 lg/mL,
respectively. The mean tmax values were 1.8 and 2.0 h,
respectively. Results for the extent of absorption, as
determined from mean AUC0–t and AUC0–? values, were
272.7 and 277.1 lg h/mL, respectively, after administra-
tion of the Test formulation and 273.4 and 277.3 lg h/mL,
respectively, after administration of the reference formu-
lation (Table 1).
The bioequivalence was evaluated by using the geo-
metric means of Cmax, AUC0–t and AUC0–? values for BIA
2-005. The ratio (test/reference) of each parameter ranged
from 96 to 101 % for both dose strengths (Table 2). Fol-
lowing 400 mg ESL, the 90 % confidence intervals for the
ratios of Cmax, AUC0–t and AUC0–? were 94–109, 94–98
and 94–98 %, respectively, meeting the predetermined
criteria for bioequivalence. Following 800 mg ESL, the
90 % confidence intervals for the ratios of Cmax, AUC0–t
and AUC0–? were 95–105, 95–103 and 95–103 %,
respectively, also meeting the predetermined criteria for
bioequivalence (Table 2).
3.3 Tolerability
A total of 40 healthy subjects were randomized to the study
with all subjects exposed to ESL. Twenty (20) subjects (11
males and 9 females) received a single oral tablet of
400 mg ESL from both MF and TBM formulations; 20
subjects (10 males and 10 females) received a single oral
tablet of 800 mg ESL of the MF formulation, but only 18
subjects received a single oral tablet of 800 mg ESL of the
TBM formulation. Two (2) subjects discontinued the study
before dosing on their second treatment period (ESL
800 mg TBM): one subject presented a positive result for
opiates due to the intake of antitussive syrup, and the other
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Fig. 1 Mean plasma concentration-time profiles of BIA 2-005
following a single oral dose of ESL 400 mg MF and TBM
(n = 20) and ESL 800 mg MF and TBM (n = 20, n = 18 for ESL
800 mg TBM). a Linear scale; b semi-log scale
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Overall, 13 treatment-emergent AEs (TEAEs) were
reported by 7 (17.5 %) subjects (2 of them presenting
TEAEs in both treatment periods). No TEAEs were
reported in the ESL 400 mg MF treatment period, two
TEAEs were reported by one subject (5.0 %) in the ESL
400 mg TBM, five TEAEs by four subjects (20.0 %) in the
ESL 800 mg MF and six TEAEs by four (22.2 %) subjects
in the ESL 800 mg TBM (Table 3). The majority of AEs
were mild in intensity and considered possibly related to
treatment.
There was no serious AE (SAE) and no important
medical event. No AE required the withdrawal of a subject,
and all subjects with TEAEs had recovered at the end of the
study. No clinically relevant difference was observed in the
nature, the intensity of TEAEs or their relationship with
ESL between both formulations.
4 Discussion
The present study demonstrated that pharmacokinetics
properties of the new ESL formulation under evaluation
were similar to the marketed ESL formulation.
When two distinct formulations of the same drug, which
obeys a linear pharmacokinetics, are alike in the rate and
extent to which its active product ingredient is absorbed
and becomes equally available at the site of action, they are
considered bioequivalent and thus assumed to be
Table 1 Summary of pharmacokinetics parameters of BIA 2-005 following administration of a single dose of ESL 400 mg and 800 mg TBM
and MF formulations
BIA 2-005 Cmax (lg/mL) Tmax (h) AUC0–t (lg h/mL) AUC0–? (lg h/mL) T1/2 (h)
400 mg ESL (MF)
Geometric mean 6.32 2.0 (0.5–6.0) 110.30 111.13 9.5
Arithmetic mean ± SD 6.46 ± 1.35 112.57 ± 23.01 113.42 ± 23.25 9.6 ± 1.4
CV % 21 59 20 21 15
400 mg ESL (TBM)
Geometric mean 6.39 2.0 (0.5–6.0) 105.85 106.62 9.4
Arithmetic mean ± SD 6.55 ± 1.52 108.22 ± 23.97 109.03 ± 24.25 9.5 ± 1.5
CV % 23 62 22 22 16
800 mg ESL (MF)
Geometric mean 12.95 2.0 (1.0–4.0) 273.47 277.27 11.9
Arithmetic mean ± SD 13.18 ± 2.22 279.04 ± 61.74 282.93 ± 63.32 12.06 ± 1.9
CV % 19 41 22 22 14
800 mg ESL (TBM)
Geometric mean 12.81 1.8 (1.0–6.0) 272.68 277.08 12.2
Arithmetic mean ± SD 12.99 ± 2.56 278.73 ± 60.18 283.39 ± 61.00 12.35 ± 1.7
CV % 17 61 22 22 16
Cmax, Maximum observed plasma concentration; Tmax, time to Cmax (value is median with range); T1/2, terminal plasma half-life; AUC0–t, area
under the concentration-time curve (AUC) from time zero to last observable concentration; AUC0–?, AUC from time zero to infinity; ESL,
eslicarbazepine acetate; MF, marketed formulation; TBM, to-be-marketed formulation
Table 2 Geometric mean ratios (GMR) and 90 % confidence intervals (90 % CI) of log-transformed data comparing test (TBM) and reference
(MF) formulations of both 400 and 800 mg ESL
Drug parameter 400 mg ESL 800 mg ESL
Ratio test (TBM)/reference (MF):
GMR (90 % CI)
Ratio test (TBM)/reference (MF):
GMR (90 % CI)
BIA 2-005
Cmax 1.01 (0.94–1.09) 1.00 (0.95–1.05)
AUC0–t 0.96 (0.94–0.98) 1.00 (0.95–1.03)
AUC0–? 0.96 (0.94–0.98) 1.00 (0.95–1.03)
Cmax, Maximum observed plasma concentration; AUC0–t, area under the concentration-time curve (AUC) from time zero to last observable
concentration; AUC0–?, AUC from time zero to infinity; ESL, eslicarbazepine acetate; MF marketed formulation; TBM, to-be-marketed
formulation
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therapeutically equivalent since this is a function of its
pharmacokinetic-pharmacodynamic relationship [18, 23–
25]. Moreover, to demonstrate bioequivalence, it is gen-
erally accepted that the 90 % confidence interval for the
ratio of means of logarithmically transformed AUC and
Cmax should lie within the range of 80–125 %, with no
differences in Tmax evaluated by a non-parametric test on
the untransformed values [26, 27].
ESL presents a pharmacokinetic profile that can be
considered linear [19, 28], and our study data revealed that
the both formulations of ESL presented similar pharma-
cokinetic characteristics. The study results show that both
ESL formulations are bioequivalent for the rate and extent
of absorption. The 90 % confidence intervals were com-
pletely contained within the predefined bioequivalence
criteria of 80–125 % for Cmax and AUC.
In general, ESL formulations were well tolerated at both
doses (400 and 800 mg) and formulations (MF and TBM)
tested, and the observed adverse events were typical of
previous studies of ESL conducted in healthy subjects.
5 Conclusion
Oral tablet formulations of either 400 or 800 mg ESL from
the new API source was found to be bioequivalent to the
corresponding marketed Zebinix formulation according to
the regulatory definition of bioequivalence.
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